| HOME >> BIOLOGY >> TECHNOLOGY |
REDWOOD CITY, Calif., March 11 /PRNewswire-FirstCall/ -- Maxygen, Inc. (Nasdaq: MAXY), a biotechnology company focused on the development of improved protein drugs, today announced that it will present at the Cowen & Company 28th Annual Health Care Conference on Tuesday, March 18, 2008 at 8:00 a.m. Eastern Time. Russell Howard, Maxygen's chief executive officer, will present. A live webcast of the presentation can be accessed on Maxygen's website at http://www.maxygen.com/webcasts. A replay of the presentation will be available for 90 days.
About Maxygen
Maxygen is a biopharmaceutical company focused on developing improved versions of protein drugs. The company's lead program, MAXY-G34, is designed to be an improved version of long-acting G-CSF for the treatment of neutropenia. MAXY-G34 is currently in Phase II clinical trials. Also in Maxygen's pipeline is a new Factor VIIa product candidate for the treatment of hemophilia and new CTLA4-Ig product candidates for the treatment of rheumatoid arthritis. Maxygen uses its proprietary DNA shuffling technology and extensive protein modification expertise to pursue the creation of biosuperior proteins. http://www.maxygen.com
| SOURCE Maxygen, Inc. Copyright©2008 PR Newswire. All rights reserved |